Clinical trial · Observational
The mCRC Patients With pMMR/MSS or dMMR/MSI-H Status Received Palliative Chemotherapy Efficacy and Survival
The Metastatic Colorectal Cancer Patients With Proficient Mismatch Repair (pMMR) / Microsatellite Stable (MSS) or Deficient Mismatch Repair (dMMR) / Microsatellite Instability High (MSI-H) Status Received Palliative Chemotherapy Efficacy and Survival
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
Deficient mismatch repair (dMMR) or microsatellite instability high (MSI-H) accounts for 4-5% in metastatic colorectal cancer (mCRC). The efficacy and survival of patients with dMMR/MSI-H status received palliative chemotherapy have not clear yet. In this study, the investigators observed the efficacy and survival of dMMR/MSI-H status mCRC patients received palliative first-line chemotherapy.
Conditions
Conditions (3)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Colorectal Cancer Metastatic | — | UNRESOLVED | — |
| Microsatellite Instability High | — | UNRESOLVED | — |
| Mismatch Repair Deficiency | — | UNRESOLVED | — |
Interventions
Interventions (0)
Data not yet available
Design
Arms and outcomes
Arms (2)
- label
- pMMR/MSS mCRC patients
- description
- The metastatic colorectal cancer patients with proficient mismatch repair or microsatellite stable status.
- label
- dMMR/MSI-H mCRC patients
- description
- The metastatic colorectal cancer patients with deficient mismatch repair or microsatellite instability high status.
Primary outcomes (1)
- measure
- Progression-Free Survival (PFS)
- timeFrame
- up to 24-36 months
- description
- PFS as measured in accordance with the Response Evaluation Criteria In Solid Tumours (RECIST) version 1.1
Secondary outcomes (3)
- measure
- Response rate
- timeFrame
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
- Maximum age
- 80 Years
Show eligibility criteria text
Inclusion Criteria: 1. Age ≥ 18 years old 2. Histologically confirmed Metastatic colorectal adenocarcinoma; 3. Immunohistochemistry confirmed mismatch repair status or polymerase chain reaction (pCR) / next-generation sequencing (NGS) confirmed microsatellite status 4. Received palliative chemotherapy and have complete information of treatment Exclusion Criteria: 1. Patients have not tested for mismatch repair or microsatellite 2. Patients have not received palliative chemotherapy or received palliative chemotherapy but treatment information incomplete
References
Publications (0)
Data not yet available